drugset / Trial / NCT05694260
A Clinical Study in Children With Heterozygous Familial Hypercholesterolemia (HeFH) Aged 6 to 17 Treated Once Daily With Bempedoic Acid Oral Dosing (CLEAR Path 1)
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Multiple-dose study to measure pharmacokinetics, pharmacodynamics and safety of bempedoic acid in pediatric participants 6 to 17 years of age with HeFH.
Timeline
- Start
- 2023-01-12
- Primary completion
- 2025-06-04
- Completion
- 2025-06-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bempedoic acid | Small molecule | 90 mg | Oral |
| Subject | Bempedoic acid | Small molecule | 150 mg | Oral |
| Subject | Bempedoic acid | Small molecule | 180 mg | Oral |